「ak sk」の検索結果

Suggests continuous subcutaneous insulin infusion (CSII) for adults with type 1 diabetes mellitus who desire increased insulin delivery flexibility or improved treatment satisfaction and are capable of using the device. Clinical triggers include statements such as 'Patient wants more lifestyle flexibility with insulin' or 'Consider pump for improved satisfaction in T1DM'.

日本語の概要は準備中です。原文の説明を表示しています。

Assesses patient’s understanding of how CGM data (trends, rates of change) differ from discrete SMBG fingerstick values. Triggered when clinicians hear requests to explain lag and trend arrows on CGM or teach the difference between CGM glucose and fingerstick glucose.

日本語の概要は準備中です。原文の説明を表示しています。

Evaluates patient-specific factors such as lifestyle, motivation, and barriers that may affect successful CGM use. Triggered when clinicians discuss patient’s readiness for CGM or identify obstacles to consistent sensor wear.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends real-time continuous glucose monitoring (RT-CGM) for adult patients with type 1 diabetes mellitus (T1DM) whose hemoglobin A1C is above individualized target. Consider when clinician notes 'T1DM A1C above goal, consider RT-CGM' or 'Patient willing to wear CGM daily, A1C elevated'.

日本語の概要は準備中です。原文の説明を表示しています。

Assesses patient’s knowledge of diabetic ketoacidosis prevention, recognition, and treatment. Triggered by clinician prompts such as 'Review sick-day rules and DKA signs' or 'Ensure patient knows when to seek help for hyperglycemia'.

日本語の概要は準備中です。原文の説明を表示しています。

Evaluates basal insulin rates through basal rate testing across different time periods and adjusts as indicated. Triggered by clinician orders to 'Perform basal rate test to verify pump settings' or 'Check basal rates during periodic pump review'.

日本語の概要は準備中です。原文の説明を表示しています。

Assesses the patient’s ability to troubleshoot insulin pump malfunctions such as occlusion, battery failure, or error messages. Trigger phrases include “Review pump alarm responses” and “Ensure patient knows steps for pump error”.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests encouraging patients to use appropriately adjusted embedded bolus calculators in CSII and to provide education regarding their use and limitations. Triggers include: 'Patient starting pump, discuss bolus calculator', 'Review bolus calculator education at pump initiation'.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests that clinicians continue CSII in hospitalized patients with type 1 or type 2 diabetes when the institution has clear protocols for evaluating pump candidates and appropriate monitoring and safety procedures. Trigger phrases include: 'Admitted patient on pump, check hospital pump policy' and 'Inpatient with diabetes using pump, verify institutional guidelines'.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends continuous subcutaneous insulin infusion (CSII) over multiple daily injections (MDI) for adults with type 1 diabetes who have achieved their A1C goal but experience severe hypoglycemia or high glucose variability, provided the patient and caregivers are willing and able to use the device. Consider CSII when clinicians hear 'A1C is at goal but patient has severe lows or glucose swings' or think 'pump for hypoglycemia-prone controlled T1DM'.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests either continuous glucose monitor (CGM) or self-monitoring of blood glucose (SMBG) for pregnant individuals with type 2 diabetes. Triggers include decisions about glucose monitoring methods for pregnant patients with T2DM needing a monitoring strategy.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends continuing insulin pump therapy in hospitals with pump expertise; otherwise transitioning to scheduled subcutaneous basal bolus insulin if anticipated length of stay exceeds 1–2 days before pump discontinuation. Consider this when anticipating a hospital stay >2 days, lacking pump expertise, or needing to conserve supplies.

日本語の概要は準備中です。原文の説明を表示しています。

Confirms patient understands that continuous glucose monitoring complements but does not replace self-monitoring of blood glucose. Triggers include: 'Clarify CGM role alongside fingersticks', 'Ensure patient knows CGM does not eliminate need for SMBG'.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests that adults with type 1 or type 2 diabetes using continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) receive education, training, and ongoing support to achieve and maintain individualized glycemic goals. Trigger phrases include: 'Patient on pump plus CGM, arrange education' and 'Ensure CSII+CGM users get training and support'.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests CSII with good adherence to monitoring and dosing for adults with type 2 diabetes mellitus who have poor glycemic control despite intensive insulin therapy, oral agents, other injectable therapy, and lifestyle modifications. Trigger phrases include 'T2DM on multiple injectables still uncontrolled' and 'Consider pump for insulin-requiring T2DM failing other therapies'.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends against routine addition of metformin to insulin for pregnant individuals with type 2 diabetes already on insulin. Triggered when considering adding metformin to an insulin regimen in pregnancy for patients with type 2 diabetes.

日本語の概要は準備中です。原文の説明を表示しています。

Assesses whether the patient has emergency supplies such as glucagon, ketone strips, and backup insulin readily available. Triggered when clinicians verify the patient carries a glucagon kit or ensure backup insulin and supplies are accessible.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends initial surgical resection of the primary lesion(s) causing Cushing's syndrome when surgery is feasible and likely to significantly reduce glucocorticoid excess. Trigger phrases include overt Cushing's syndrome, ACTH-dependent CS, ectopic ACTH secretion, adrenal adenoma, bilateral macronodular adrenal hyperplasia, and persistent hypercortisolism.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends steroidogenesis inhibitors as second-line treatment after transsphenoidal surgery (TSS) in Cushing's disease, as primary therapy for occult or metastatic ectopic ACTH syndrome (EAS), and as adjunctive cortisol reduction in adrenocortical carcinoma. Use when evaluating CS patients post‑TSS, with occult/metastatic EAS, or ACC; triggers include “persistent hypercortisolism after TSS,” “occult EAS,” and “adjunctive for ACC.”

日本語の概要は準備中です。原文の説明を表示しています。

Suggests repeat transsphenoidal surgery for patients with persistent hypercortisolism after initial transsphenoidal surgery when imaging shows evidence of incomplete resection or a pituitary lesion. Clinical triggers include postoperative MRI revealing residual adenoma, persistent elevated UFC or late-night salivary cortisol, and visible pituitary lesion on imaging.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends additional treatments for patients with persistent overt hypercortisolism after initial surgical intervention for Cushing's syndrome. Trigger phrases include "post-op CS patient shows ongoing hypercortisolism," "persistent overt hypercortisolism after TSS," and "elevated UFC or midnight salivary cortisol following surgery."

日本語の概要は準備中です。原文の説明を表示しています。

Advises surgical referral for parathyroid carcinoma when feasible after achieving control of severe hypercalcemia. Triggered when a clinician confirms parathyroid carcinoma and inquires about curative options following medical stabilization of hypercalcemia.

日本語の概要は準備中です。原文の説明を表示しています。

Determines whether to recommend unilateral laparoscopic adrenalectomy or medical therapy with a mineralocorticoid receptor antagonist for patients with confirmed unilateral PA (aldosterone-producing adenoma or unilateral adrenal hyperplasia). Triggered when discussing treatment options after confirming unilateral PA in a hypertensive patient with hypokalemia or resistant hypertension.

日本語の概要は準備中です。原文の説明を表示しています。

Identifies patients with a positive aldosterone-to-renin ratio screening who may proceed directly to subtype testing without confirmatory testing based on specific clinical criteria. Triggers include spontaneous hypokalemia, baseline plasma aldosterone concentration >100 pg/mL (CLEIA), renin suppression, or a clinician questioning the need for a confirmatory test after a positive screen.

日本語の概要は準備中です。原文の説明を表示しています。